An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa

Study site 100, Sofia

Study site 101, Sofia

Study site 102, Zagreb

Study site 103, Zagreb

Study site 108, Brno

Study site 107, Liberec

Study site 104, Olomouc

Study site 105, Prague

Study site 106, Prague

Study site 115, Bordeaux

Study site 129, Caen

Study site 125, Chambéry

Study site 110, Clermont-Ferrand

Study site 123, Dijon

Study site 124, Lille

Study site 111, Lyon

Study site 126, Marseille

Study site 120, Nancy

Study site 121, Nantes

Study site 113, Nîmes

Study site 119, Paris

Study site 130, Paris

Study site 118, Poitiers

Study site 117, Reims

Sudy site 122, Rennes

Study site 109, Rouen

Study site 112, Strasbourg

Study site 128, Toulouse

Study site 114, Tours

Study site 131, Budapest

Study site 132, Dublin

Study site 133, Dublin

Study site 136, Bologna

Study site 134, Brescia

Study site 138, Catania

Study site 140, Milan

Study site 137, Palermo

Study site 135, Pisa

Study site 139, Vicenza

Study site 145, Baia Mare

Study site 141, Bucharest

Study site 143, Craiova

Study site 146, Iași

Study site 142, Timișoara

Study site 147, Ljubljana

Study site 151, A Coruña

Study site 150, Alicante

Study site 152, Barcelona

Study site 149, Madrid

Study site 154, Málaga

Study site 156, Oviedo

Study site 153, Salamanca

Study site 157, Valencia

Study site 155, Valladolid

Study site 158, Zaragoza

Study site 159, Belfast